NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
Clinical Trials
6 trialsNCT04430894 2026-01-29
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03499808 2025-09-09
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT02990338 2025-01-17
ICARIA-MM
Sanofi
Phase 3 Completed
NCT03194867 2024-06-14
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Sanofi
Phase 1/2 Completed
NCT02812706 2024-04-01
Islands
Sanofi
Phase 1/2 Completed